Sanj Patel Sells 2,141 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 2,141 shares of the stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $54.01, for a total value of $115,635.41. Following the completion of the sale, the chief executive officer owned 431,904 shares in the company, valued at approximately $23,327,135.04. The trade was a 0.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Up 1.5%

Shares of NASDAQ KNSA traded up $0.79 during midday trading on Thursday, hitting $53.78. The company’s stock had a trading volume of 861,409 shares, compared to its average volume of 707,651. The business’s 50 day moving average is $46.26 and its two-hundred day moving average is $43.04. Kiniksa Pharmaceuticals International, plc has a 12-month low of $24.85 and a 12-month high of $54.31. The firm has a market cap of $4.12 billion, a P/E ratio of 72.68 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to the consensus estimate of $207.12 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.Kiniksa Pharmaceuticals International’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period last year, the business posted $0.11 EPS. On average, analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.09 earnings per share for the current fiscal year.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and raised guidance — Kiniksa reported EPS and revenue above Street estimates and lifted FY‑2026 revenue guidance, signaling stronger near‑term growth driven by ARCALYST. Earnings & Guidance Release
• Positive Sentiment: Multiple analyst price‑target increases — brokers have raised targets (examples: Canaccord to $64, Citigroup to $60, Wedbush to $59, Wells Fargo to $57), reflecting upgraded revenue/earnings assumptions and supporting buy‑side interest. Canaccord Note More Analyst Notes
• Positive Sentiment: Product momentum and pipeline — management increased ARCALYST expectations after strong net product revenue, and KPL‑387 Phase 2 readout (recurrent pericarditis) and a planned Phase 3 could be meaningful catalysts later in 2026. Pipeline Release
• Positive Sentiment: Market sentiment lift — media coverage notes improved investor sentiment following the “healthcare surprise,” drawing renewed interest in the stock. Kalkine Media
• Neutral Sentiment: Earnings materials available — slide deck and call transcript provide detail on channel dynamics and assumptions; useful for validating management’s guidance and margin outlook. Earnings Presentation
• Negative Sentiment: Insider sale — Director Barry D. Quart sold 13,099 shares under a pre‑arranged Rule 10b5‑1 plan, cutting his stake ~51%; while planned, such selling can create short‑term sentiment pressure. SEC Filing

Analyst Upgrades and Downgrades

Several research firms have commented on KNSA. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Sunday. Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Citigroup raised their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $60.86.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC boosted its position in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter valued at $31,000. Smartleaf Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at $36,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at $41,000. Finally, CIBC Private Wealth Group LLC bought a new stake in Kiniksa Pharmaceuticals International during the 4th quarter valued at $41,000. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.